Achondroplasia
Conditions
Keywords
Achondroplasia, Dwarfism
Brief summary
TransCon CNP administered once-weekly in children and adolescents with achondroplasia who have completed a prior TransCon CNP clinical trial. Participants who complete a prior TransCon CNP trial and meet all eligibility criteria will be invited to continue into the long-term open label extension trial to receive 100 µg CNP/kg/week of TransCon CNP. Trial treatment will be completed when the participant reaches 16 years of age for females and 18 years of age for males and have femur and tibial epiphyseal closure. TransCon CNP treatment will continue if femur and tibial epiphyseal closure is not confirmed at the age of 16 years for females, and 18 years for males. Treatment with TransCon CNP will be completed once femur and tibial epiphyseal closure is confirmed by radiographic imaging. The trial duration is individual for each trial participant. Visits will occur every 12-14 weeks throughout the trial.
Interventions
DRUGTransCon CNP
TransCon CNP drug product is a lyophilized powder in a single-use vial. Prior to use, the lyophilized powder is reconstituted with sterile water for injection and administered by subcutaneous injection via syringe and needle.
Sponsors
Ascendis Pharma Growth Disorders A/S
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
Patients will roll over from previous TransCON CNP clinical trials
Eligibility
Sex/Gender
ALL
Age
3 Years to 15 Years
Healthy volunteers
No
Inclusion criteria
* Written, signed informed consent of the parent(s) or legal guardian(s) of the participant, and as required by the institutional review board/human research ethics committee/independent ethics committee (IRB/HREC/IEC). For participants who are below the age of consent, a written assent will be obtained in accordance with applicable requirements as required by IRB/HREC/IEC. Upon reaching the legal age of consent, depending on applicable requirements, these participants will be asked to give their own written consent. * Participants with achondroplasia who have completed a clinical trial with TransCon CNP. * Parent(s)/legal guardian(s) willing and able to administer weekly SC injections of TransCon CNP and to follow the protocol. * Considered eligible based on the safety evaluations performed for evaluating stopping/holding rule criteria during the prior TransCon CNP clinical trial.
Exclusion criteria
* Known or suspected hypersensitivity to the investigational product or related products (trehalose, tris\[hydroxymethyl\]aminomethane, succinate, and methoxy polyethylene glycol \[mPEG\]). * Have received any dose of prescription medications, investigational medicinal product (other than TransCon CNP). * Sexually active female participants and female partners of male participants of childbearing potential not using a highly effective form of contraceptive (including oral, injectable, or implantable contraception, or intrauterine device (IUD)) for the entire trial period and for 90 days post end of the trial. * Participants with serum 25-hydroxy-vitamin D (25OHD) levels of \<50 nmol/L (\<20 ng/mL) at Visit 1 must be on treatment regimen of Vitamin D supplementation. * Any disease or condition that, in the opinion of the investigator, may make the participant unlikely to fully complete the trial, may confound interpretation of trial results, or may present undue risk from receiving trial treatment. This could include family situations, complications or manifestations, or medications that might impact safety or be considered confounding.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety and Tolerability | Through trial completion, an average of 10 years | Incidence of Treatment-Emergent Adverse Events |
| Height Z-scores | Through trial completion, an average of 10 years | Number of standard deviations |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Annualized Growth Velocity | Through trial completion, an average of 10 years | cm per year |
Countries
Australia, Austria, Canada, Denmark, France, Germany, Ireland, New Zealand, Portugal, Spain, United Kingdom, United States
Contacts
STUDY_DIRECTORMedical Director, MD
Ascendis Pharma A/S
Outcome results
None listed